secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001628280-25-047342
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q3 net product rev $851M (+103% YoY); raises 2025 guidance 10% to $2.95-3.05B
--------------------------------------------------------------------------------

- Total net product revenues $851M (+103% YoY); TTR franchise $724M (+135% YoY) led by AMVUTTRA ATTR-CM launch.
- GAAP net income $251M ($1.84 diluted EPS) vs loss of $111.6M; non-GAAP net income $396M ($2.90 EPS).
- 2025 guidance raised: total net product revs $2.95B-$3.05B (10% midpoint increase); TTR rev guidance $2.475B-$2.525B.
- Initiated ZENITH Phase 3 for zilebesiran in hypertension and TRITON-PN Phase 3 for nucresiran in hATTR-PN.
- Appointed Bryan Supran EVP & Chief Legal Officer; issued $661M convertible notes; received subpoena on government price reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/0001628280-25-047342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/alny-20251030.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-047342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer